Clinical data supports continued development of ORENCIA administration for rheumatoid arthritis
Links shared publicly online about this topic.
- 1,659total visits
Clinical data supports continued development of ORENCIA administration for rheumatoid arthritis
Bristol-Myers Squibb Company announced today that new clinical data support continued development of a subcutaneous administration of ORENCIA® (abatacept) for patients with moderate to severe rheumatoid arthritis.
View full resource at news-medical.net
Tags: Cancer, Lung Cancer, Lung, Arthritis, Rheumatoid Arthritis, Rheumatoid Arthritis Medication, Orencia, Bristol-Myers Squibb
Most Recently Shared on October 22, 2009 at 4:16 am By:
Lung Cancer News: Clinical data supports continued development of ORENCIA administration for r.. http://digg.com/u1EoVC
Advertisement
